Just one year after it was established, the new policy office in the US FDA’s Office of New Drugs is demonstrating its value in the high-stakes setting of the COVID-19 pandemic.
The Office of New Drug Policy is one of the cross-functional support offices created by the FDA’s broad modernization initiative...






